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Background: High-dose chemotherapy (HDT) was added to conventional chemotherapy in Ewing sarcoma family
tumor (EFT) patients, poor responders (PRs) to induction chemotherapy in order to improve their survival.
Patients and methods: Patients aged £40 years with nonmetastatic Ewing sarcoma (ES) received vincristine (V),
doxorubicin (A), cyclofosfamide (C), actinomycin (Ac), ifosfamide (I) and etoposide (E) (VACAc-IE regimen) as induction
chemotherapy. As maintenance treatment, good responders (GR) received nine cycles of VACAc-IE regimen. PRs
received three cycles of VAC-IE, mobilizing cycle with CE and HDT with Busulfan and Melphalan with stem cell
support.
Results: Three hundred patients [median age 15 years (3–40 years)] entered the study. One patient refused local
treatment, 242 (81%) underwent surgery [with radiotherapy (RT) in 80] and 57 (19%) RT alone. No toxic deaths
were recorded. Overall GR were 146 (49%). Twenty-eight PR did not receive HDT. At a median follow-up of 64 months
(21–116 months), 5-year overall and event-free survival (EFS) were 75% and 69%, respectively. Five-year EFS was
75% for GR, 72% for PR treated with HDT and 33% for PR who did not receive HDT.
Conclusions: High-dose therapy added to the VACA-IE regimen in PR patients is feasible and effective. Selected
groups of patients with ES can benefit from HDT.
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introduction
Ewing sarcoma family tumors (EFT) are rare small round cell
tumors arising either in bone or soft tissues. Usually, they occur
in children, adolescents and young adults, and in these age
groups, they are the second most common bone cancer [1].
Chemotherapy treatment of patients with EFT has been
based for decades on a four-drug combination of vincristine,
doxorubicin, cyclophosphamide and actinomycin D (VACAc
regimen) [2, 3]. Some studies replaced cyclophosphamide
with ifosfamide, and others added ifosfamide and/or
etoposide [4–7]. A randomized study comparing the
VACAc regimen with the VACAc + ifosfamide/etoposide
(VACAc/IE) combination demonstrated that in
nonmetastatic patients, the six-drug regimen offers the best
survival probability [8]. Recurrence can be expected in >30% of
patients [4, 8–10]. Retrospective analyses have shown that
chemotherapy-induced tumor necrosis is predictive of survival
[4, 7, 9, 11, 12], suggesting the need of a different
chemotherapy strategy in patients showing poor sensitivity to
primary chemotherapy.
In the nineties, several studies with the use of high-dose
chemotherapy (HDT) followed by autologous stem cell
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reconstitution reported interesting, although, contradictory
results [13–21].
In 1999, the Italian Sarcoma Group (ISG) and the
Scandinavian Sarcoma Group (SSG) activated a joint study.
Treatment strategy was based on the primary use of the six
drugs, active against EFT. For poor responder (PR) patients,
treatment intensification with the addition of HDT was added.
The results of this study are reported here.
patients and methods
Patient selection
Patients aged £40 years with biopsy-proven histological diagnosis of EFT
without synchronous metastases were eligible for the study.
Written informed consent was obtained before starting the protocol.
Presence of synchronous metastases [as assessed by means of technetium bone
scan, computed tomography (CT) of the chest and bone marrow aspirates],
medical contraindication to the drugs used in the protocol and a delay of >4
weeks from biopsy to beginning of treatment were exclusion criteria.
All patients had a biopsy-proven diagnosis of Ewing sarcoma (ES)/
primitive neuroectodermal tumor carried out by a pathologist from the
referral centers (ISG) or confirmed by expert pathology panel (SSG).
Pretreatment tumor evaluation included conventional X-rays, CT and/or
magnetic resonance imaging of the entire involved bone. These were
repeated after primary chemotherapy, before local treatment. The stage of
the disease was assessed by means of technetium bone scan, CT of the chest
and bone marrow aspirates and biopsy.
study design
The ISG/SSG III study identified two different risk groups of patients on the
basis of tumor response to primary chemotherapy.
All patients underwent primary chemotherapy consisting of the six
drugs: vincristine (V), doxorubicin (A), cyclophosphamide (C),
actinomycin (Ac), ifosfamide (I) and etoposide (E).
After primary chemotherapy, tumor assessment, local control procedures
and evaluation of tumor response were centralized in referral centers.
Surgery was the preferred treatment of local control. Radiotherapy (RT)
alone was reserved for tumors where the possibility achieving adequate
surgical margins was excluded. Tumor response assessment was based on
evaluation of the grade of primary chemotherapy-induced tumor necrosis
for surgery or on radiographic tumor regression for those patients who
received RT as local treatment only.
Good responder (GR) patients continued treatment with the same drugs
delivered in the primary phase. PR patients underwent ‘salvage’
chemotherapy with the addition of HDT and peripheral blood stem cells
support.
The study protocol was approved by the ethical committee of the
participating institutions.
treatment plan
The chemotherapy outline is reported in Figure 1.
The use of HDT was excluded in case of tumor progression during
chemotherapy. A minimum CD34+ cell harvest of 2.5 · 106/kg was
requested to proceed to the high-dose treatment.
Local therapy was planned after four courses of primary chemotherapy.
Surgery was the treatment of choice and when site or dimensions excluded
the possibility of adequate surgical margins, radiotherapy alone was given.
The total radiation dose was 54 Gy, 1.5 Gy twice daily, 5 days/week/36
fractions. When surgical margins were inadequate, postoperative
radiotherapy was recommended with a total dose of 42 Gy (1.5 Gy twice
daily, 5 days/week/28 fractions).
Radical and wide margins were considered adequate, while marginal,
intralesional and contaminated margins were inadequate [22].
Chemotherapy-induced tumor necrosis was evaluated according to
a method previously reported [12]. When macroscopic foci of viable tumor
cells were present, pathologic regression was graded I, when isolated
microscopic nodules of viable tumor cells were detected, it was graded II
and in absence of viable tumor, it was graded III. Patients with pathologic
response grades II and III were classified as GR and PR were grade I.
When pathologic response was not assessable, response to primary
chemotherapy was based on radiological response. A retrospective ISG/SSG
analysis of combined histological and radiological evaluation of 55 patients
revealed a strong correlation between total disappearance of the soft tissue
component and a good histological response [23]. Therefore, complete
disappearance of the soft tissue component identified GR patients.
statistical analysis
Aims of the study were to evaluate event-free survival (EFS) in patients with
nonmetastatic EFT receiving a treatment based on primary chemotherapy
response, to assess chemotherapy-induced tumor necrosis and to correlate
chemotherapy response to survival. EFS was defined as the period from the
start of chemotherapy to the most recent follow-up or local or systemic
recurrence or death from treatment-related complications or secondary
malignancy. Overall survival (OS) was calculated from the start of
chemotherapy to the most recent follow-up or death. Survival curves were
calculated according to the Kaplan and Meier method and compared using
the log-rank test. Analysis of toxicity was carried out by means of chi-
square test or Fisher’s exact test.
results
From June 1999 to December 2006, 300 patients from eight
centers in Scandinavia and seven centers in Italy entered the
study. Follow-up data were updated to June 2009. Patient
characteristics are reported in Table 1. Median age was 15 years
and 38% of patients were adults (18 years or older). There was
a male predominance. The most frequently involved sites were
femur, pelvis, tibia and humerus. Overall, 53% of EFT were
Chemotherapy Outline 
VAC  IVAc  VAC     IE   Local treatment 
0 3 6 9 12 week 
Good Responders 
VAC  IVAc     IE      VAC   IVAc    IE      VAC     IVAc    IE   
13 16 19 22 25 28 31 34 37  week 
Poor Responders 
VAC   CE*     VAC     IE     BuMel 
13 16 19 22 25 
Figure 1. Italian Sarcoma Group/Scandinavian Sarcoma Group III. V,
vincristine1.5 mg/m2 (top dose 2 mg); A, doxorubicin 80 mg/m2; C,
cyclofosfamide 1200 mg/m2; Ac, actinomycin D1.5 mg/m2; I, ifosfamide 9
g/m2, E, etoposide 450 mg/m2; CE*, cyclophosphamide 4 g/m2 and
etoposide 600 mg/m2; BuMel, busulfan 4mg/kg · 4 days orally and
melphalan 140 mg/m2.
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located in an extremity, 28% had an axial location and 19%
were pelvic.
In 15 cases, diagnosis was made after inadequate surgery for
a lesion deemed as benign or after laminectomy for
neurological complications secondary to the spine location of
the tumor. In all cases, a persistence of soft tissue component
was documented before study entry.
Overall, 242 (81%) patients underwent surgery, 12 had
a limb amputation, 1 had a rotation plasty and 229 (95%) were
resected.
In two children, on demand of the surgeon in order to carry
a surgical reconstruction to save the growth plate, surgery was
postponed after chemotherapy completion. In six patients, all
with pelvic tumors, full-dose radiotherapy was given after
primary chemotherapy and surgery was delayed after
chemotherapy completion. Of the 15 cases treated with surgery
before the beginning of systemic therapy, 10 patients received
radiotherapy as definitive local treatment, 4 underwent
a subsequent tumor resection and 1, a 4-year-old boy with the
tumor located to the spine who achieved complete radiologic
response, did not receive further local therapy.
All patients who received up-front surgery had intralesional
surgical margins. Evaluation of surgical margins was carried out
in 219 of the remaining patients. One hundred and seventy-
seven (81%) patients had adequate margins, 32 (15%) marginal
and 10 (5%) intralesional.
Overall, 80 patients underwent surgery and radiotherapy. In
addition to the 10 patients who underwent immediate surgery,
postoperative radiotherapy was given to the 42 patients with
inadequate surgical margins and, on a clinical basis,
radiotherapy was added in 22 patients whose tumor was
resected with clean margins. In six patients, full-dose
radiotherapy was given after primary chemotherapy and
surgery was carried out after chemotherapy completion.
Radiotherapy only was used in 57 (19%) patients. Overall, the
median received dose of radiotherapy was 54 Gy (36–64 Gy). In
case of radiotherapy only, it was 54 Gy (36–54 Gy) and 45 Gy
(41–61 Gy) in surgically treated patients. The median received
dose was 54 Gy (41–64 Gy) in patients who received high-dose
therapy with busulfan and melphalan.
One patient refused local treatment and received
chemotherapy only.
Type and timing of local treatment has been summarized in
Figure 2.
Tumor site significantly (P < 0.001) influenced the method of
local control. Surgery alone was more frequently used in
extremity located tumors (surgery 79%, surgery and
radiotherapy 18% and radiotherapy 3%), and radiotherapy was
more frequently used for pelvic lesions (surgery 25%, surgery
and radiotherapy 18% and radiotherapy 57%), whereas tumors
with central locations were more likely to receive surgery and
radiotherapy (surgery 27%, surgery and radiotherapy 48% and
radiotherapy 25%).
Overall, 146 (49%) patients were classified as GR to primary
chemotherapy. Six (2%) patients did not complete primary
chemotherapy due to local or systemic tumor progression. The
remaining 148 (49%) patients were classified as PR to primary
chemotherapy.
Evaluation of histological response to primary chemotherapy
was carried out in 220 patients who received surgery at the time
scheduled by the protocol (i.e. after the four courses of primary
treatment). Tumor necrosis was grade I in 110 (50%), grade II
in 46 (21%) and grade III in 64 (29%) patients. Histological
response was not assessed in three patients who were treated as
GR as a result of the radiographic response evaluation.
Histological assessment of the response was not applicable in 8
patients who received surgery at the end of the chemotherapy
and in 10 who received surgery up front.
A good response was more frequently observed in children,
female and patients with an extremity location of the tumor
(Table 2).
The type of local treatment significantly (P = 0.001) differed
according to tumor response: surgery only, combined
treatment of surgery and radiotherapy and radiotherapy only
were used in 66%, 18% and 16% of patients with a good
response, respectively. In those patients with a poor
response, the percentages were 44%, 34% and 22%,
respectively.
At a median follow-up of 64 months (range 21–116 months),
209 (70%) patients were continuously event free. No acute
treatment-related deaths were registered. One patient died of
sepsis after pneumonia, 10 months after HDT completion.
Acute myeloid leukemia developed in two patients, 13 and 20
Table 1. Patient characteristics
Characteristics n (%)
Age (years)
Median (minimum–maximum) 15 (3–40)
Age groups (years)
3–9 51 (17)
10–17 136 (45)
‡18 113 (38)
Sex
Male 192 (64)
Female 108 (36)
Site
Femur 49 (16)
Pelvis 56 (19)
Tibia 38 (12)
Humerus 29 (10)
Rib 26 (9)
Spine 24 (8)
Soft tissues 19 (6)
Scapula 15 (5)
Fibula 14 (5)
Other 30 (10)
LDHa
Normal 181 (68)
High 84 (32)
SAPb
Normal 239 (89)
High 29 (11)
aAvailable in 265 patients.
bAvailable in 268 patients.
LDH, lactate dehydrogenase; SAP, serum alkaline phosphatase.
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months after chemotherapy completion (both patients received
surgery as local therapy: one had a good histological response
and the second had poor histological response, but he refused
high-dose treatment and completed chemotherapy with the
same scheme used for GR). Local disease progression alone was
documented in 14 patients; bone metastases and lung
metastases were reported in 15 and 21 patients, respectively. In
36 patients, tumor recurrence involved multiple sites.
Insufficient data were available to define the pattern of
recurrence in two patients.
The 5-year EFS rate was 69% [95% confidence interval (CI)
63% to 74%]. The 5-year OS rate was 75% (95% CI 70% to
80%). Table 3 reports the probability of EFS according to
different variables.
According to response to primary chemotherapy, patients
with good response had a 5-year EFS rate of 75% (95% CI 68%
to 82%) and the remaining patients had a 5-year EFS rate of
63% (95% CI 55% to 70%).
Overall, 154 patients were classified as PR patients. Twenty-
eight patients did not receive HDT. Ten patients had tumor
progression during standard chemotherapy, four (three males
aged 13, 15 and 22 years, respectively, and one female 21 years
old) had poor harvest of CD34+ cells, four refused the
procedure, three had medical contraindications (one male 6
years old with radionecrosis of the chest wall, one male 19 years
old with Bullous pulmonary lesions and one female 26 years old
with aortic insufficiency) and seven were excluded on a clinical
basis of the treating center. All patients completed the
chemotherapy program as GR.
The probability of 5-year EFS for the 126 PR patients who
could intensify treatment with HDT was 72% (95% CI 64% to
80%). PR patients who were given standard chemotherapy had
a 5-year EFS of 33% (95% CI 11% to 55%) (Figure 3).
toxicity
No toxic deaths were reported. One patient died of sepsis, 10
months after HDT completion, but the relationship with
chemotherapy was not proven.
After conventional VAC-IVAc-IE courses, grade 4 leukopenia
and thrombocytopenia were 66% and 7%, respectively. Overall,
hospitalization for chemotherapy toxicity was needed after 17%
of courses.
After the mobilizing course CE, all patients experienced
grade 4 leukopenia (neutropenic fever in 38%) and 45% grade
4 thrombocitopenia. Red blood cell or platelet transfusions
300 Patients 
Radiotherapy 
57 patients 
Surgery  + 
Radiotherapy 
80 patients 
No local treatment 
1 patient 
Surgery 
162 patients 
Surgery upfront 
and Radiotherapy 
10 patients 
Surgery after 
Radiotherapy 
6 patients 
Radiotherapy after 
definitive surgery 
64 patients 
Surgery upfront+ 
definitive surgery 
4 patients 
Surgery upfront 
1 patient 
Surgery after  
Chemotherapy 
completion 
2 patients 
Surgery after 
induction chemo 
155 patients 
Figure 2. Type and timing of local treatment.
Table 2. Response to primary chemotherapy according to clinical
characteristics
GR (%) PR (%) P value
Gender 0.04
Male 85 (44) 107 (56)
Female 61 (56) 47 (44)
Age (years) <0.001
3–9 36 (71) 15 (29)
10–17 74 (54) 62 (45)
‡18 36 (32) 77 (68)
Site 0.05
Extremity 86 (54) 73 (46)
Central 60 (43) 81 (57)
SAPa 0.9
High 14 (48) 15 (52)
Normal 113 (47) 126 (53)
LDHb 0.3
High 44 (52) 40 (48)
Normal 81 (45) 100 (55)
aAvailable in 268 patients.
bAvailable in 265 patients.
GR, good responders; LDH, lactate dehydrogenase; PRs, poor responders;
SAP, serum alkaline phosphatase.
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were required in 66% and 40% of courses. The median CD34+
collected cells were 7.2 · 106/kg (range 1.4–23).
After HDT, 94% of patients had grades 3–4 mucositis, red
blood cell (77%) or platelet (95%) transfusions were required
for most patients. The median time to reach a platelet count
>50 · 109/l and leukocyte count >1.5 · 109/l were13.5 (9–40)
and 11 (4–38) days, respectively. Epileptic seizures were
reported in one patient. Transient laboratory findings
suggesting a hepatic veno-occlusive disease were reported in six
patients. Permanent gonadal damage was observed in all
postpuberal patients who underwent high-dose therapy.
Four PR patients experienced a remarkable radiotherapy
toxicity. One patient after chest wall irradiation developed
a severe radionecrosis, which did not allow the use of high-dose
therapy. Two patients had a radiation-induced colitis requiring
partial colectomy. One patient was treated locally with surgery
and radiation therapy (total dose 45 Gy) and the other with
radiation therapy alone (total dose 54 Gy). One patient with
tumor located to the thoracic spine had transverse myelitis after
radiotherapy (total dose 42 Gy). The three former patients
received intensified treatment with HDT.
discussion
ISG/SSG III was a joint study aimed to explore survival in
patients with nonmetastatic ES treated with a chemotherapy-
adapted protocol based on the response to induction
chemotherapy.
The histological response to primary chemotherapy is the
main predictive factor of survival in localized EFT. In the
French experience, patients with a good histological response
had a probability of 5-year EFS of 75% compared with 40% and
20%, respectively, for intermediate or poor histological
response [9]. Final results of the CESS-86 study reported
a 10-year probability of EFS of 64% for patients with a good
histological response and 38% for PR patients [7]. In the Italian
experience, the reported 10-year EFS was 75% in GR patients
compared with 27% in PR patients [4].
Different strategies of treatment are certainly needed in PR
patients.
In the last years, interesting and promising results have been
reported by the use of HDT and peripheral blood stem cell
rescue in patients with ES.
The first experience was reported in the 1988 [13] in patients
with metastatic disease. Afterward, several papers described the
use of HDT in high-risk (synchronous metastases or recurrent
disease) patients with EFT [13–21]. The results were
contradictory with some reports [15, 18, 21], suggesting an
activity of megatherapy in EFT, but the scientific community
has not yet reached an agreement on the use of HDT in EFT.
Since 1999, a randomized trial whose main objective is to
establish the role of megatherapy in EFT is ongoing [24]. More
recently, the activity of HDT in patients with EFT has been
described in two European studies: the first included patients
with recurrent disease and the second with synchronous
metastatic disease [25, 26].
ISG and SSG agreed on the clinical relevance of the
effectiveness of HDT in high-risk EFT patients. The strategy of
treatment was characterized by the selective use of HDT in
patients with poor response to primary chemotherapy based on
the VACA/IE regimen. Protocol INT-0091 (CCG-7881 and
POG-8850) [8] had clearly shown that the VACA/IE regimen
was more effective compared with the VACA regimen. A
Rizzoli monoinstitutional study carried out in the early nineties
showed that in spite of the primary use of the VACA/IE
regimen, only 50% of patients obtained a good histological
response [27]. The present multicentric study confirmed these
data.
Table 3. EFS probability
Variable % 5-year EFS
(95% CI)
P value
Age (years) 0.04
3–9 77 (65–89)
10–17 71 (64–79)
‡18 62 (52–71)
Sex 0.9
Male 68 (62–75)
Female 69 (60–78)
Site 0.8
Extremity 68 (60–75)
Central 72 (62–82) 0.8
Pelvis/sacrum 67 (55–80)
LDHa 0.005
Normal 73 (67–80)
High 58 (48–69)
Local treatment 0.001
Surgery 71 (64–78)
Surgery and radiotherapy 76 (66–85)
Radiotherapy 53 (40–66)
Response 0.01
Good response 75 (68–82)
Poor responseb 63 (55–70)
aAvailable in 265 patients.
bIncluding patients who progressed during primary chemotherapy.
CI, confidence interval; EFS, event-free survival; LDH, lactate
dehydrogenase.
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Figure 3. Event-free survival according to response to primary
chemotherapy and to high-dose chemotherapy.
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In the ISG/SSG III study, a relation between age and
chemotherapy-induced tumor necrosis was observed. Children
(age < 18 years) were more likely to have a good response to
primary chemotherapy than adults. These data confirm those
reported in a retrospective monoinstitutional analysis [28].
For different reasons, 19% of PR patients could not be given
the planned chemotherapy with high-dose treatment. Ten
patients did not receive HDT due to tumor progression during
standard chemotherapy and eventually died of diseases within
12 months from tumor progression. It is interesting to note
that the remaining PR patients who did not receive HDT had
a probability of 5-year EFS of 33% (95% CI 11% to 55%). This
percentage is in the same range as that previously observed in
studies in which PR patients received conventional
chemotherapy [4, 7, 9].
A major observation from this study is that PR patients who
received HDT had a 5-year EFS of 72% (95% CI 64% to 80%),
similar to the 5-year EFS of 75% achieved in GR patients.
The results of our study confirm the importance of the
response to primary chemotherapy in EFT and suggest that
a strategy of salvage chemotherapy in PR patients is feasible and
effective. Overall, the reported results are better than those
obtained in previous SSG and ISG experience [4, 29, 30].
The present data do not come from a randomized study and
the comparison with the group of patients who could not
receive HDT in ISG/SSG III study and that with historical series
are not statistically adequate. For this reason, they should be
considered with caution.
No treatment-related deaths were recorded. Previous large
multicentric studies with conventional chemotherapy reported
an incidence of toxic deaths ranging from 0.6% to 3% [8, 31,
32]. In our opinion, the decision of centralizing patients in
referral centers has certainly contributed to the feasibility of the
treatment. Some cautions should be addressed to the potential
additional risk in terms of late side-effects, namely possible
higher incidence of second malignancies by the use of high-
dose therapy. Furthermore, the gonadal failure is a high price
that patients undergoing such a sterilizing treatment have to
pay. Sperm banking in men and cryopreservation and
reimplantation of ovarian tissue in women are recommended
procedures that may reduce the impact of the expected
infertility in patients undergoing high-dose treatment.
A probability of EFS at 5 years 70% has been reported with
protocols based on conventional chemotherapy [8, 31]. In our
opinion, it is important to underline that the adult population
included in the cited studies was only 13%–14%, respectively
[8, 31], and that the study population was dominated by
pediatric patients, who it well recognized, have better prognosis
in EFT [4, 9, 10], whereas in the ISG/SSG III study, 40% of the
population were adults (age > 18 years).
If we compare our results with those of a recent European
multicentric study, with conventional chemotherapy, a 5-year
EFS close to 70% is reported only for a minority (155 of 647,
24%) of patients having small tumors and classified as
standard-risk patients, whereas a 5-year EFS <60% was
reported for the remaining localized patients [32].
In conclusion, the present study showed that the use of HDT
in PR patients to the VACA/IE regimen is feasible and effective.
The probability of survival obtained with this study in PR
patients is higher than that obtained in historical series. The
present data support the use of HDT in selected risk groups of
EFT patients.
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